We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Single‐Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B‐Cell Lymphoma.
- Authors
Desai, Sanjal; Chaturvedi, Mansi; Hameed, Rumaisa; Baez‐sosa, Valentina; Shenoy, Aarthi G.
- Abstract
Outcomes of diffuse large B‐cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single‐center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose‐adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA‐EPOCH‐R) comparative with de novo DLBCL. Of 170 patients with DLBCL, 136 were de novo, 17 were concurrent, and 17 were transformed. Transformed DLBCL had significantly lower complete response rates and progression‐free survival (PFS) but similar overall survival (OS) compared with de novo counterpart. There was no significant difference between de novo and concurrent DLBCL regarding response rates, PFS, and OS. DA‐EPOCH‐R was associated with inferior OS. Thus, intensified treatment with DA‐EPOCH‐R might not improve outcomes of transformed DLBCL. This article reports characteristics of concurrent and transformed diffuse large B cell lymphoma (DLBCL) and comparative outcomes after dose adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA‐EPOCH‐R).
- Subjects
ETOPOSIDE; RITUXIMAB; DISEASE progression; COMBINATION drug therapy; DOXORUBICIN; B cell lymphoma; RETROSPECTIVE studies; TREATMENT effectiveness; CANCER patients; CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE; EVALUATION
- Publication
Oncologist, 2021, Vol 26, Issue 9, pe1660
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1002/onco.13846